Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer

Cancer

Volumn 120, Issue 5, 2014, Pages 642-651

  Welslau, Manfred ^a   Diéras, Veronique ^b   Sohn, Joo Hyuk ^c   Hurvitz, Sara A ^d   Lalla, Deepa ^e   Fang, Liang ^e,g   Althaus, Betsy ^e   Guardino, Ellie ^e   Miles, David ^f  

^a Medical Office Hematology   (Germany)

^b INSTITUT CURIE   (France)

^c Yonsei University College of Medicine   (South Korea)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e GENENTECH INC   (United States)

^f MOUNT VERNON CANCER CENTRE   (United Kingdom)

^g GILEAD SCIENCES   (United States)

Author keywords

ado trastuzumab emtansine; antibody drug conjugate; breast cancer; HER2 positive; quality of life; T DM1

Indexed keywords

BO 21977; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TDM 4370G; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; METASTASIS POTENTIAL; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT ATTITUDE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SENSITIVITY ANALYSIS; SURVIVAL RATE;

ADO-TRASTUZUMAB EMTANSINE; ANTIBODY-DRUG CONJUGATE; BREAST CANCER; HER2-POSITIVE; QUALITY OF LIFE; T-DM1;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DIARRHEA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HEALTH STATUS; HUMANS; MAYTANSINE; MEDICATION ADHERENCE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; QUINAZOLINES; RECEPTOR, ERBB-2; SELF REPORT; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84896704753     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28465     Document Type: Article

References (27)

1. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008; 68: 9280-9290.
2. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX,. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011; 128: 347-356.
3. Barok M, Tanner M, Köninki K, Isola J,. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett. 2011; 306: 171-179.
4. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367: 1783-1791. Erratum in N Engl J Med. 2013;368:2442.
5. Lipscomb J, Gotay CC, Snyder CF,. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer J Clin. 2007; 57: 278-300.
6. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006; 7: 903-909.
7. Basch E, Jia X, Heller G, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009; 101: 1624-1632.
8. Agresta S, Hurvitz S, Lalla D, et al. Patient-reported outcomes (PROs) in HER2+ metastatic breast cancer (MBC) treated with T-DM1. Ann Oncol. 2010; 21 (suppl 8): v111345. Abstract 1117.
9. Hurvitz S, Dirix L, Kocsis J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013; 31: 1157-1163. Erratum in J Clin Oncol. 2013;31:2977.
10. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997; 15: 974-986.
11. Yost KJ, Sorensen MV, Hahn EA, Glendenning GA, Gnanasakthy A, Cella D,. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. Value Health. 2005; 8: 117-127.
12. Yost KJ, Eton DT,. Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof. 2005; 28: 172-191.
13. Chambers KK, McMillan SC,. In: Frank-Stromborg M, Olson SJ, eds. Instruments for Clinical Health-Care Research. ed 2. Boston: Jones & Bartlett Publishers; 1997: 487-497.
14. Gwede CK, James JL, Zachariah B, et al. Quality of life (QOL), bowel symptoms and function assessments in patients undergoing chemoradiation for anal or rectal cancer: RTOG 0315. Presented at: 14th Annual Congress of the International Society for Quality of Life Research, Toronto, Canada, October 10-13, 2007. Abstract 1597.
15. Eton DT, Cella D, Yost KJ, et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol. 2004; 57: 898-910.
16. Brookmeyer R, Crowley J,. A confidence interval for the median survival time. Biometrics. 1982; 38: 29-41.
17. Littell RC, Milliken GA, Stroup WW, et al. SAS for Mixed Models. 2nd ed. Cary, NC: SAS Institute Inc; 2006.
18. Blyth CR, Still HA,. Binomial confidence intervals. J Am Stat Assoc. 1983; 78: 108-116.
19. Casella G,. Refining binomial confidence intervals. Can J Stat. 1986; 14: 113-129.
20. Mantel N, Haenszel W,. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22: 719-748.
21. Cella D, Wang M, Wagner L, Miller K,. Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100). Breast Cancer Res Treat. 2011; 130: 855-861.
22. Corey-Lisle PK, Peck R, Mukhopadhyay P, et al. Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer. Cancer. 2012; 118: 461-468.
23. Sherrill B, Di Leo A, Amonkar MM, et al. Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. Curr Med Res Opin. 2010; 26: 767-775.
24. Fairclough L,. Design and Analysis of Quality of Life Studies in Clinical Trials. ed 2. Boca Raton, FL: Taylor & Francis Group; 2010.
25. Siddiqui O, Hung HM, O'Neill R,. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat. 2009; 19: 227-246.
26. Osoba D, Hsu MA, Copley-Merriman C, et al. Stated preferences of patients with cancer for health-related quality-of-life (HRQOL) domains during treatment. Qual Life Res. 2006; 15: 273-283.
27. White CB, Smith ML, Abidoye O, Lalla D,. Examining patient treatment choices involving efficacy, toxicity, and cost tradeoffs in the metastatic breast cancer setting. Cancer Res. 2012; 72 (24 suppl): 542s. Abstract P6-09-11.